

# DYDROEASE-20 SR

Dydrogesterone 20 mg (as Sustained Release Tablets)



Ease Your Life With

**Do**uble  
se

La Renon



# DYDROEASE-20 SR

Dydrogesterone 20 mg (as Sustained Release Tablets)

## CLINICAL EVIDENCE - 1

**Objective :** Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice.

**Design :** Multicenter observational study

**Total Patients :** 996 women

**Dosage :** 10 mg once or twice daily

**Duration :** 6 months

**Results :**




Fig.1 Changes in duration of MC during treatment.




Fig.2 Changes in menstrual pain intensity and anxiety with Dydrogesterone treatment.

- MC duration was significantly improved in all patient subgroups.
- Patient grading of pain intensity and anxiety level during menstruation decreased significantly at EOT.
- Dydrogesterone was associated with high or very high patient satisfaction (89.6%); the clinical response was considered good or excellent (85.8%).

**Conclusion :** Dydrogesterone therapy was effective in achieving MC regularization and reducing menstrual pain and anxiety, during both treatment and 6-month FU.

# CLINICAL EVIDENCE - 2

**Objective :** To compare the effectiveness of 2 different treatment regimens of Dydrogesterone in the management of endometriosis related chronic pelvic pain.

**Design :** Observational, prospective cohort study

**Total Patients :** 350 women with endometriosis and chronic pelvic pain with or without dysmenorrhea.

**Dosage :** Dydrogesterone 10 mg 2 or 3 times daily

**Duration :** 6 months

**Results :** A marked reduction in chronic pelvic pain was observed with both the prolonged cyclical and continuous treatment regimens. With both regimens patients experienced significant improvements in the intensity of chronic pelvic pain, number of days in which analgesics were required, severity of dysmenorrhea, sexual well-being, and health-related quality-of-life parameters.




Fig.1 Days per cycle when analgesics needed.




Fig.2 Severity of Chronic Pelvic pain (FAS)

**Conclusion :** Prolonged cyclical and continuous regimens of Dydrogesterone were similarly effective in their ability to reduce chronic pelvic pain, the requirement for analgesics, and the severity of dysmenorrhea in women with endometriosis.

Reference : Fertility and sterility, 116(6), 1568–1577

\*NRS - numerical rating scale



# DYDROEASE-20 SR

Dydrogesterone 20 mg (as Sustained Release Tablets)

Also Available

**DYDROEASE**

Dydrogesterone 10 mg Tablets

**DYDROEASE-30 SR**


Dydrogesterone 30 mg Tablets (as Sustained Release)

## DESCRIPTION :

Each film coated Sustained Release tablet contains Dydrogesterone 20 mg.

## INDICATION :

For Progesterone Deficiencies :



## DYDROEASE BENEFITS :

- Rapid onset of action.
- Bioavailability is 5.6 times better than oral MCP (Micronized Progesterone).
- 1.5 times better affinity than oral MCP.
- It has no oestrogenic, androgenic, anabolic and corticoid properties.
- Better half-life of 5-7 hours imparting long and stable effect.
- Reduced pill burden.

## DOSAGE :

As directed by the physician.

Scan for more  
Prescribing Information



La Renon Healthcare Private Limited

207 - 208 Iscon Elegance | Circle P | Prahlad Nagar Cross Roads | S.G. Highway | Ahmedabad - 380015 | Gujarat | India.  
Phone : + 91-79-6616-8998 | 2693-6656 | Fax : +91-79-6616-8998 | E-mail : info@larenon.com | Web : www.larenon.com

© 2024 All rights reserved, La Renon Healthcare Private Limited

